Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07043972 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

A Phase 2 study of Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
55
Enrollment target
2
Study locations

NCT07043972 is a Phase 2 study of Urothelial Carcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 55 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07043972, a Phase 2 study of Urothelial Carcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
55 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and pembrolizumab (EVP). It will also learn about the efficacy and safety of GC in these patients. The main questions it aims to answer are: * Does GC shrink the cancer or stop it from growing? * What medical side effects do participants have while receiving GC? Researchers will study how GC affects survival, cancer control, and quality of life. They will also collect blood samples to look at health-related markers and cancer DNA in the blood. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Participants will: * Receive the GC chemotherapy (gemcitabine and cisplatin) after having been treated with EVP * Visit the clinic regularly for checkups, lab tests, and scans * Answer questions about their health, quality of life, and daily function * Provide blood samples for research This study may help researchers find better ways to treat advanced bladder and urinary tract cancer in the future-especially for older adults or those who have already tried other treatments.

Conditions Studied

Urothelial Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Gemcitabine

Study Locations (2)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia
  • Temple University Hospital at Broad Street - Philadelphia

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2025-07-09
Est. Completion 2031-01-01
Phase Phase 2

Sponsor

Fox Chase Cancer Center

183 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07043972

The ClinicalTrials.gov registry entry for NCT07043972 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (77% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.

NCT07043972 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07043972 about?

NCT07043972 is a clinical study titled "Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma". The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and pembrolizumab (EVP). It will also learn about the efficacy and safety of GC...

What is the current status of trial NCT07043972?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2025-07-09. Estimated completion is 2031-01-01.

What conditions does trial NCT07043972 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

What interventions are being tested in trial NCT07043972?

The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT07043972?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07043972 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Carcinoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.